In the past week, OLMA stock has gone down by -7.54%, with a monthly decline of -23.87% and a quarterly plunge of -23.44%. The volatility ratio for the week is 7.14%, and the volatility levels for the last 30 days are 9.72% for Olema Pharmaceuticals Inc. The simple moving average for the past 20 days is -3.98% for OLMA’s stock, with a -19.37% simple moving average for the past 200 days.
Is It Worth Investing in Olema Pharmaceuticals Inc (NASDAQ: OLMA) Right Now?
Moreover, the 36-month beta value for OLMA is 1.93. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OLMA is 49.58M and currently, short sellers hold a 17.27% of that float. On December 10, 2024, OLMA’s average trading volume was 502.55K shares.
OLMA) stock’s latest price update
Olema Pharmaceuticals Inc (NASDAQ: OLMA)’s stock price has dropped by -9.67 in relation to previous closing price of 10.45. Nevertheless, the company has seen a loss of -7.54% in its stock price over the last five trading days. globenewswire.com reported 2024-12-09 that SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OP-3136, a novel small molecule that potently and selectively inhibits KAT6, a validated epigenetic target that is dysregulated in breast and other cancers.
Analysts’ Opinion of OLMA
Many brokerage firms have already submitted their reports for OLMA stocks, with Goldman repeating the rating for OLMA by listing it as a “Buy.” The predicted price for OLMA in the upcoming period, according to Goldman is $24 based on the research report published on April 02, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see OLMA reach a price target of $20. The rating they have provided for OLMA stocks is “Buy” according to the report published on January 30th, 2024.
Oppenheimer gave a rating of “Outperform” to OLMA, setting the target price at $21 in the report published on July 21st of the previous year.
OLMA Trading at -14.61% from the 50-Day Moving Average
After a stumble in the market that brought OLMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.73% of loss for the given period.
Volatility was left at 9.72%, however, over the last 30 days, the volatility rate increased by 7.14%, as shares sank -23.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.56% lower at present.
During the last 5 trading sessions, OLMA fell by -7.54%, which changed the moving average for the period of 200-days by -30.02% in comparison to the 20-day moving average, which settled at $9.83. In addition, Olema Pharmaceuticals Inc saw -32.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OLMA starting from Paradigm Biocapital Advisors L, who sale 2,400,000 shares at the price of $14.91 back on Aug 01 ’24. After this action, Paradigm Biocapital Advisors L now owns 783,118 shares of Olema Pharmaceuticals Inc, valued at $35,796,000 using the latest closing price.
Harmon Cyrus, the Director of Olema Pharmaceuticals Inc, sale 4,066 shares at $15.58 during a trade that took place back on Jul 29 ’24, which means that Harmon Cyrus is holding 752,217 shares at $63,348 based on the most recent closing price.
Stock Fundamentals for OLMA
Current profitability levels for the company are sitting at:
- -72.14 for the present operating margin
- 0.86 for the gross margin
The net margin for Olema Pharmaceuticals Inc stands at -65.12. The total capital return value is set at -0.68. Equity return is now at value -51.76, with -46.92 for asset returns.
Currently, EBITDA for the company is -104.58 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 268.95. The receivables turnover for the company is 2.74for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.10.
Conclusion
To wrap up, the performance of Olema Pharmaceuticals Inc (OLMA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
